AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

CLARITY PHARMACEUTICALS LTD

2.480

-0.140-5.34%

Volume:2.46M

Turnover:6.11M

Market Cap:922.63M

PE:-8.79

High:2.600

Open:2.580

Low:2.440

Close:2.620

52wk High:5.870

52wk Low:1.800

Shares:372.03M

Float Shares:274.26M

Volume Ratio:1.43

T/O Rate:0.90%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.282

EPS(LYR):-0.201

ROE:-53.45%

ROA:-30.54%

PB:3.96

PE(LYR):-12.31

Loading ...

Overview Company News Filings

Clarity Pharmaceuticals Ltd - Signs Commercial Manufacturing Agreement for Cu-64 SAR-Bispsma With Nucleus Radiopharma

THOMSON REUTERS

ASX Growth Companies With High Insider Ownership In April 2026

Simply Wall St.

Clarity Pharmaceuticals Ltd-Director Appointment/Resignation

THOMSON REUTERS

Stock Track | Clarity Pharmaceuticals Soars 5.65% Intraday on Positive Prostate Cancer Imaging Trial Results

Clarity Co-PSMA trial shows 64Cu-SAR-bisPSMA PET doubles detection vs 68Ga-PSMA-11

Why 4DMedical, Brazilian Rare Earths, Clarity, and Tuas shares are racing higher today

BRIEF-Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement

Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move

Clarity Pharmaceuticals Signs Large-Scale Copper-64 Manufacturing Supply Agreement With Theragenics

MT Newswires Live

BUZZ-Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply

3 ASX healthcare stocks tipped to soar over 100% higher this year

Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares

Exciting clinical news for this ASX healthcare stock earns it a buy recommendation

Clarity Co-PSMA trial shows 64Cu-SAR-bisPSMA lifts positive scan rate by 42 percentage points versus 68Ga-PSMA-11

Why is this ASX 300 stock rocketing 17% today?

Why Clarity Pharmaceuticals (ASX:CU6) Is Up 7.0% After AMPLIFY Trial Consent Completion And What's Next

Simply Wall St.

Clarity Pharmaceuticals Valuation After AMPLIFY Trial Recruitment Surges Past Initial Target

Simply Wall St.

Registrational Phase Iii Amplify Trial: Target Number of Participants Achieved

THOMSON REUTERS

Clarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial

MT Newswires Live

Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/stock/CU6.AU/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CU6.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","market":"AU","secType":"STK","nameCN":"CLARITY PHARMACEUTICALS LTD","latestPrice":2.48,"timestamp":1787292720000,"preClose":2.62,"halted":0,"volume":2460943,"delay":0,"changeRate":-0.05343511450381684,"nameEN":"CLARITY PHARMACEUTICALS LTD","floatShares":274264090,"shares":372030071,"eps":-0.282253,"marketStatus":"Market Closed","change":-0.14,"latestTime":"08-21 16:12:00 AEST","open":2.58,"high":2.6,"low":2.44,"amount":6112772,"amplitude":0.061069,"askPrice":2.5,"askSize":3000,"bidPrice":2.47,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.282253,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1787529600000},"marketStatusCode":7,"adr":0,"exchange":"ASX","adjPreClose":2.62,"openAndCloseTimeList":[[1787270400000,1787292000000]],"volumeRatio":1.434727314908569,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"CU6.AU","preClose":2.62,"auctionPrice":2.48,"auctionVolume":86670,"auction":3,"marketStatus":"盘后竞价","timestamp":1787292600774}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"CU6.AU\",,,,,undefined,":{"symbol":"CU6.AU","floatShares":274264090,"roa":"-30.54%","roe":"-53.45%","lyrEps":-0.201427,"volumeRatio":1.434727314908569,"shares":372030071,"dividePrice":0,"high":2.6,"amplitude":0.061069,"preClose":2.62,"low":2.44,"week52Low":1.8,"pbRate":"3.96","psRate":"87.21","week52High":5.87,"institutionHeld":0,"latestPrice":2.48,"committee":0.25,"eps":-0.282253,"divideRate":0,"volume":2460943,"delay":0,"ttmEps":-0.282253,"open":2.58,"prevYearClose":3.38,"prevWeekClose":2.63,"prevMonthClose":2.37,"prevQuarterClose":2.14,"fiveDayClose":2.63,"twentyDayClose":2.35,"sixtyDayClose":2.43,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CU6.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CU6.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CU6.AU\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2627646902","title":"Clarity Pharmaceuticals Ltd - Signs Commercial Manufacturing Agreement for Cu-64 SAR-Bispsma With Nucleus Radiopharma","url":"https://stock-news.laohu8.com/highlight/detail?id=2627646902","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627646902?lang=en_us&edition=fundamental","pubTime":"2026-04-14 06:34","pubTimestamp":1776119645,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260413:nFWN40W0IV:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627093751","title":"ASX Growth Companies With High Insider Ownership In April 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2627093751","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627093751?lang=en_us&edition=fundamental","pubTime":"2026-04-13 03:08","pubTimestamp":1776020881,"startTime":"0","endTime":"0","summary":"As the Australian market remains steady amidst global geopolitical developments, investors are keeping a close eye on growth companies with strong insider ownership that could offer resilience in uncertain times. In such a landscape, firms where insiders hold significant stakes may align their interests closely with shareholders, potentially providing stability and confidence to investors navigating these complex conditions.","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/8041000-choice2-main-header/1585186556238"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/software/asx-eol/energy-one-shares/news/asx-growth-companies-with-high-insider-ownership-in-april-20","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7016","AR1.AU","AV1.AU","EOL.AU","TOR.AU","BK7017","BK7095","BK7104","BK7067","BK7096","BK7110","FRS.AU","FEX.AU","BK7129","BK7508","IMA.AU","BK7007","AEM.AU","CYC.AU","CUV.AU","MAU.AU","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626978711","title":"Clarity Pharmaceuticals Ltd-Director Appointment/Resignation","url":"https://stock-news.laohu8.com/highlight/detail?id=2626978711","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626978711?lang=en_us&edition=fundamental","pubTime":"2026-04-09 06:57","pubTimestamp":1775689037,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260408:nTUE9C5VNQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181835965","title":"Stock Track | Clarity Pharmaceuticals Soars 5.65% Intraday on Positive Prostate Cancer Imaging Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1181835965","media":"Stock Track","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181835965?lang=en_us&edition=fundamental","pubTime":"2026-04-01 12:37","pubTimestamp":1775018248,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd. (CU6.AU) saw its stock price surge 5.65% during intraday trading on Wednesday, following the release of encouraging clinical trial data for its prostate cancer imaging...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_en","symbols":["CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624675555","title":"Clarity Co-PSMA trial shows 64Cu-SAR-bisPSMA PET doubles detection vs 68Ga-PSMA-11","url":"https://stock-news.laohu8.com/highlight/detail?id=2624675555","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2624675555?lang=en_us&edition=fundamental","pubTime":"2026-04-01 05:38","pubTimestamp":1774993109,"startTime":"0","endTime":"0","summary":"Clarity reported European Urology publication of Co-PSMA Phase II trial results, previously presented at EAU Congress 2026.Study showed copper-64 SAR-bisPSMA PET/CT with next-day imaging detected more cancer sites than gallium-68 PSMA-11 in men with early biochemical recurrence following prostate removal.Improved detection shifted planned treatment decisions in 44% of patients, supporting broader use in low-PSA relapse where standard PSMA scans often miss disease.Clarity positioned data as supportive of commercialization plans for SAR-bisPSMA, with Phase III AMPLIFY readout pending.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260331:nNDL9FG6l3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622043920","title":"Why 4DMedical, Brazilian Rare Earths, Clarity, and Tuas shares are racing higher today","url":"https://stock-news.laohu8.com/highlight/detail?id=2622043920","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622043920?lang=en_us&edition=fundamental","pubTime":"2026-03-25 10:35","pubTimestamp":1774406118,"startTime":"0","endTime":"0","summary":"In afternoon trade, theS&P/ASX 200 Index is on course to record a strong gain. At the time of writing, the benchmark index is up 1.95% to 8,544.3 points.Four ASX shares that are rising more than most today are listed below. Here's why they are racing higher:. The 4DMedical share price is up 34% to $6.21. Investors have been buying this respiratory imaging technology company's shares after it made a big announcement. 4DMedical revealed that its CT:VQ technology has been deployed at the Mayo Clinic in the United States. The company's managing director and CEO, Andreas Fouras, commented: \"Mayo's deployment is uniquely significant. When the world's number one hospital chooses to use your technology, it sends the strongest possible signal to the entire U.S. healthcare market about the clinical value and readiness of CT:VQ.\". The Tuas share price is up 5.5% to $6.33. This morning, this Singapore-based telco released its half-year results for FY 2026. Tuas revealed a 25.5% increase in revenue","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/25/why-4dmedical-brazilian-rare-earths-clarity-and-tuas-shares-are-racing-higher-today/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/25/why-4dmedical-brazilian-rare-earths-clarity-and-tuas-shares-are-racing-higher-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["XJO.AU","CU6.AU","TUA.AU","BRE.AU","BK7096","BK7042","BK7095","BK7094","4DX.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622010055","title":"BRIEF-Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2622010055","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622010055?lang=en_us&edition=fundamental","pubTime":"2026-03-25 09:40","pubTimestamp":1774402827,"startTime":"0","endTime":"0","summary":"BRIEF-Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply AgreementMarch 25  - Clarity Pharmaceuticals Ltd CU6.AX:CLARITY SIGNS A LARGE-SCALE MANUFACTURING SUPPLY AGREEMENTCLARITY SIGNS A LARGE-SCALE MANUFACTURING SUPPLY AGREEMENT FOR COPPER-64 WITH THERAGENICSFurther company coverage: CU6.AX ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nFWN40C117:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CU6.AU","BK7096"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622290010","title":"Clarity Pharmaceuticals shares are up 12% today. Here's what's driving the move","url":"https://stock-news.laohu8.com/highlight/detail?id=2622290010","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622290010?lang=en_us&edition=fundamental","pubTime":"2026-03-25 09:36","pubTimestamp":1774402582,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  shares are up around 12% today , extending a strong run that has seen the share price rise roughly 41% over the past year.The catalyst for today's move was Clarity's announcement of a large scale manufacturing agreement with US based company Theragenics, which gives Clarity access to a 134,000 square foot production facility with 14 cyclotrons capable of producing copper 64 at scale.This is a meaningful step for a company transitioning from clinical development toward potential commercialisation.Clarity's lead prostate cancer imaging product is currently in Phase III trials. As the company moves closer to potential approval, the focus increasingly shifts from clinical progress to execution.Manufacturing capacity is a critical part of that equation.Theragenics alone has the capacity to produce enough copper 64 for around 2,000 patient doses per day per cyclotron.However, the core risk remains unchanged. The lead product is still unapproved, and regulatory outcom","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/25/clarity-pharmaceuticals-shares-are-up-12-today-heres-whats-driving-the-move/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/25/clarity-pharmaceuticals-shares-are-up-12-today-heres-whats-driving-the-move/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622014369","title":"Clarity Pharmaceuticals Signs Large-Scale Copper-64 Manufacturing Supply Agreement With Theragenics","url":"https://stock-news.laohu8.com/highlight/detail?id=2622014369","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622014369?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:49","pubTimestamp":1774396146,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals  said it has signed a large-scale manufacturing supply agreement for copper-64 with Theragenics, according to a Wednesday Australian bourse filing.The company said the agreement relates to Theragenics' 134,000-square-foot production facility near Atlanta, Georgia, which houses 14 cyclotrons for centralized, large-scale copper-64  production.The supply agreement is ahead of the anticipated commercial launch of Cu-64-SAR-bisPSMA, subject to successful completion of Clarity's phase three registrational trials and subsequent Food and Drug Administration  new drug application  approval, the filing added.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","BK7096","CU6.AU","COPX","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2622117220","title":"BUZZ-Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply","url":"https://stock-news.laohu8.com/highlight/detail?id=2622117220","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622117220?lang=en_us&edition=fundamental","pubTime":"2026-03-25 07:38","pubTimestamp":1774395511,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply** Shares of Australia's Clarity Pharmaceuticals CU6.AX rise as much as 8.5% to A$3.33** Stock hits biggest intraday pct gain since March 17** The radiopharma firm signs an agreement with Cancer Research company, Theragenics, for copper-64 ** Copper64 is used by biopharma companies to detect cancer-causing agents and for early treatment** Despite moves, stock down 3.6% YTD","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL6N40C1FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620818702","title":"3 ASX healthcare stocks tipped to soar over 100% higher this year","url":"https://stock-news.laohu8.com/highlight/detail?id=2620818702","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620818702?lang=en_us&edition=fundamental","pubTime":"2026-03-18 12:59","pubTimestamp":1773809940,"startTime":"0","endTime":"0","summary":"ASX healthcare stocks are a popular option for investors seeking defensive assets with long-term structural growth.These shares can offer portfolio diversification, drive high margins, and some of them have huge potential upside.Here are three ASX healthcare stocks on my radar this week, and analysts are tipping upside well over 100% over the next 12 months.The beaten-down medical imaging technology stock has dropped another 1.7% in Wednesday afternoon trade, to $125.69 a piece. The decline is part of a long string of declines off the back of sector-wide headwinds, which have seen the share price crash 62% from an all-time high recorded in mid-2025.Sentiment didn't improve when the company posted a record-breaking half-year FY26 result in mid-February. Its revenue was up 28%, and profit jumped nearly 30%, but it still missed investors' high expectations.Analysts are excited about the prospects for growth of the ASX healthcare stock's business fundamentals and share price over the next ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/3-asx-healthcare-stocks-tipped-to-soar-over-100-higher-this-year/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/3-asx-healthcare-stocks-tipped-to-soar-over-100-higher-this-year/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","TLX.AU","BK7094","CU6.AU","BK7096","PME.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620011984","title":"Buy, hold, sell: Clarity Pharmaceuticals, New Hope, and Orica shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2620011984","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620011984?lang=en_us&edition=fundamental","pubTime":"2026-03-18 07:33","pubTimestamp":1773790437,"startTime":"0","endTime":"0","summary":"Brokers have been busy looking over a number of ASX shares this week.Let's see what they are saying about the three named below, which have released updates in recent days. Here's what you need to know:. As a result, the broker has reaffirmed its speculative buy rating and $6.40 price target on its shares. It said:. The stage is now set for a readout from the approval study for 64Cu-SAR-bisPSMA  which has now ceased accepting new patient consents and is practically fully enrolled . The Co-PSMA data along with data from COBRA and anticipated findings from AMPLIFY will form the basis of submission of a new drug application to be submitted to the FDA.CU6 has three fast track designations for the SAR-bisPSMA agent which includes patients with BCR of prostate cancer following definitive therapy. The company is well funded with cash in excess of $226m at 31 Dec 2025.In light of this, the broker has retained its hold rating with a $5.00 price target. It said:. With leverage to attractive indu","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/buy-hold-sell-clarity-pharmaceuticals-new-hope-and-orica-shares/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/buy-hold-sell-clarity-pharmaceuticals-new-hope-and-orica-shares/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NHC.AU","BK7096","CU6.AU","BK7083","BK7017","ORI.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620062204","title":"Exciting clinical news for this ASX healthcare stock earns it a buy recommendation","url":"https://stock-news.laohu8.com/highlight/detail?id=2620062204","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620062204?lang=en_us&edition=fundamental","pubTime":"2026-03-18 06:17","pubTimestamp":1773785827,"startTime":"0","endTime":"0","summary":"ASX healthcare stock Clarity Pharmaceuticals Ltd  is in the spotlight this week.  Yesterday, the company released positive news around its new imaging agent.Let's back up and provide a little context.Clarity Pharmaceuticals specialises in the development of Targeted Copper Theranostics  for the imaging and treatment of selected cancers.In particular the company works on identification of certain cancer biomarkers. They develop technology to target those biomarkers with either small molecules or monoclonal antibodies.The company has been engaged in a clinical study.The study is evaluating the diagnostic performance of the company's 64Cu-SAR-bisPSMA PET imaging agent. The agent aims to detect recurrent prostate cancer in men with rising prostate-specific antigen  levels after initial treatment.Yesterday, the company released an announcement that the agent showed a 71% true positive rate, meaning that 7 out of 10 positive scans were confirmed as cancer, compared with only 29% for the olde","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/18/exciting-clinical-news-for-this-asx-healthcare-stock-earns-it-a-buy-recommendation/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/18/exciting-clinical-news-for-this-asx-healthcare-stock-earns-it-a-buy-recommendation/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK4217","CU6.AU","BK4533","BK4585","BK7096","BK4084","PSA","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620427285","title":"Clarity Co-PSMA trial shows 64Cu-SAR-bisPSMA lifts positive scan rate by 42 percentage points versus 68Ga-PSMA-11","url":"https://stock-news.laohu8.com/highlight/detail?id=2620427285","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620427285?lang=en_us&edition=fundamental","pubTime":"2026-03-17 21:05","pubTimestamp":1773752718,"startTime":"0","endTime":"0","summary":"Clarity reported Phase II Co-PSMA investigator-initiated trial results that were presented at the EAU Congress 2026 by Louise Emmett. In a head-to-head comparison in 50 patients with biochemical recurrence and PSA 0.2–0.75 ng/mL, 24-hour 64Cu-SAR-bisPSMA PET/CT showed a higher mean per-patient lesion count than 68Ga-PSMA-11 . The 64Cu-SAR-bisPSMA scan was positive in 78% of participants versus 36% with 68Ga-PSMA-11, a difference of 42 percentage points. Planned patient management changed in 44% of participants after review of the 64Cu-SAR-bisPSMA next-day imaging results. Clarity said the Co-PSMA data, along with results from its Phase II COBRA trial and the Phase III AMPLIFY study, are intended to support an FDA submission for 64Cu-SAR-bisPSMA in biochemical recurrence prostate cancer.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for i","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260317:nNDL6CsXTx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620418415","title":"Why is this ASX 300 stock rocketing 17% today?","url":"https://stock-news.laohu8.com/highlight/detail?id=2620418415","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620418415?lang=en_us&edition=fundamental","pubTime":"2026-03-17 07:59","pubTimestamp":1773705549,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals Ltd  shares are having a strong session on Monday.In early trade, the ASX 300 stock jumped as much as 17% to $4.26 before pulling back.Investors appear to be responding positively to an update from the company regarding new trial data for its prostate cancer imaging technology.The company revealed that results from the Co-PSMA study were presented at the European Association of Urology  Annual Congress 2026 in London. The data has also been accepted for publication in the European Urology journal.The trial evaluated Clarity's diagnostic product, 64Cu-SAR-bisPSMA, in patients experiencing biochemical recurrence of prostate cancer after surgery.Importantly, the study compared the ASX 300 stock's imaging technology with a current standard-of-care PSMA PET scan.The ASX 300 stock's executive chair, Dr Alan Taylor, commented:. The extraordinary quality of the academic research is coupled with the feverish pace of commercialisation where our registrational Phase III tr","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"motleyfoolau_stock","url":"https://www.fool.com.au/2026/03/17/why-is-this-asx-300-stock-rocketing-17-today/","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2026/03/17/why-is-this-asx-300-stock-rocketing-17-today/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619510486","title":"Why Clarity Pharmaceuticals (ASX:CU6) Is Up 7.0% After AMPLIFY Trial Consent Completion And What's Next","url":"https://stock-news.laohu8.com/highlight/detail?id=2619510486","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619510486?lang=en_us&edition=fundamental","pubTime":"2026-03-16 03:14","pubTimestamp":1773602085,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals recently reported that its pivotal Phase III AMPLIFY trial for prostate cancer imaging agent 64Cu-SAR-bisPSMA has now consented more than the planned number of participants in the US and Australia, and has stopped new consents pending final enrolment confirmation.\nThis rapid completion of participant consent, building on data from earlier COBRA and Co-PSMA studies, underscores strong clinical interest in 64Cu-SAR-bisPSMA as Clarity pursues potential FDA approval for a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/why-clarity-pharmaceuticals-asxcu6-is-up-70-after-amplify-tr","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/why-clarity-pharmaceuticals-asxcu6-is-up-70-after-amplify-tr","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4528","BK4543","BK4023","BK7096","AI","BK4588","BK4551","BK4585","CU6.AU","BK4587","AIYY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618336821","title":"Clarity Pharmaceuticals Valuation After AMPLIFY Trial Recruitment Surges Past Initial Target","url":"https://stock-news.laohu8.com/highlight/detail?id=2618336821","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618336821?lang=en_us&edition=fundamental","pubTime":"2026-03-12 16:37","pubTimestamp":1773304633,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) is back in focus after announcing its Phase III AMPLIFY trial of 64Cu-SAR-bisPSMA for prostate cancer recurrence has recruited more participants than originally planned in the US and Australia.\nSee our latest analysis for Clarity Pharmaceuticals.\nThe AMPLIFY recruitment update and recent conference appearance follow a mixed earnings release and a period of strong share price momentum, with a 30 day share price return of 15.90% and a 1 year total shareholder...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice1-main-header/1585186685410"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-valuation-after-amplify-trial-recrui","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/au/pharmaceuticals-biotech/asx-cu6/clarity-pharmaceuticals-shares/news/clarity-pharmaceuticals-valuation-after-amplify-trial-recrui","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618953699","title":"Registrational Phase Iii Amplify Trial: Target Number of Participants Achieved","url":"https://stock-news.laohu8.com/highlight/detail?id=2618953699","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618953699?lang=en_us&edition=fundamental","pubTime":"2026-03-10 21:02","pubTimestamp":1773147720,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260310:nTUA1B1T4L:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7096","CU6.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618601573","title":"Clarity Pharmaceuticals Hits Participant Target in Phase 3 Prostate Cancer Diagnostic Agent Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2618601573","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2618601573?lang=en_us&edition=fundamental","pubTime":"2026-03-10 09:38","pubTimestamp":1773106735,"startTime":"0","endTime":"0","summary":"Clarity Pharmaceuticals (ASX:CU6) said it achieved the target number of participants for its phase 3 Amplify trial for copper-64-SAR-bisPSMA positron emission tomography in participants with rising or","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4084","BK4585","PSA","BK4533","BK4217","CU6.AU","BK7096","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616804550","title":"Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2616804550","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2616804550?lang=en_us&edition=fundamental","pubTime":"2026-03-02 12:27","pubTimestamp":1772425659,"startTime":"0","endTime":"0","summary":"An organic growth in Australian healthcare services is likely due to improving availability of bulk-billing general practitioners, offset by ongoing wage pressures, Jefferies said in a Monday report.I","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["SHL.AU","BK7089","IMM.AU","FPH.AU","XAO.AU","BK7103","IDX.AU","XBI","XKO.AU","HLS.AU","COH.AU","CSL.AU","BK7126","ANN.AU","MVF.AU","BK4585","LABU","BK4588","BK7007","BK7501","BK7067","CU6.AU","NHF.AU","XLV","BK7511","BK7096","BK7508","BK7124","BK7509","BK4581","TLX.AU","BK7113","MSB.AU","CUV.AU","RHC.AU","HCAR","NEU.AU","XJO.AU","REG.AU","MPL.AU","SIG.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":48,"code":"91000000","status":"200"}]}}